Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus paclitaxel for second-line treatment of gastric cancer
ChiCTR2100041782Phase 4Recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and paclitaxel in gastric cancer (GC), sponsored by Hubei Cancer Hospital. Primary endpoint: Progression-free survival (PFS). Started Jan 2021; status: recruiting.
02
Drugs
Rivoceranibpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2100041782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041782.